Revolution Medicines (NASDAQ:RVMD) Stock Gets Price Target Increase from Royal Bank Of Canada

Posted by Francis Steltz on Oct 8th, 2026

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price objective hoisted by stock analysts at Royal Bank Of Canada from $251.00 to $259.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price points to a potential upside of 40.47% from the company’s previous close.

RVMD has been the subject of a number of other reports. Brookline Capital Markets began coverage on Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 price target for the company. Guggenheim boosted their target price on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, August 28th. Needham & Company LLC raised their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Oppenheimer upped their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. Finally, Truist Financial raised their target price on Revolution Medicines from $239.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Revolution Medicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $234.76.

Check Out Our Latest Analysis on Revolution Medicines

Revolution Medicines Stock Performance

NASDAQ:RVMD traded down $16.50 during mid-day trading on Thursday, hitting $184.38. The company’s stock had a trading volume of 1,111,558 shares, compared to its average volume of 2,854,246. The business’s fifty day moving average is $203.91 and its two-hundred day moving average is $169.34. The stock has a market cap of $39.52 billion, a price-to-earnings ratio of -20.93 and a beta of 1.40. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. Revolution Medicines has a 1 year low of $47.28 and a 1 year high of $224.31.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the firm posted ($1.31) earnings per share. Analysts anticipate that Revolution Medicines will post -8.87 EPS for the current fiscal year.

Insider Activity

In related news, insider Stephen Kelsey sold 92,531 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $202.36, for a total value of $18,724,573.16. Following the completion of the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at approximately $59,064,027.36. This represents a 24.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elizabeth M. Anderson sold 10,143 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the sale, the director owned 4,333 shares of the company’s stock, valued at $836,442.32. This trade represents a 70.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 290,991 shares of company stock worth $59,422,765. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of RVMD. Cooper Financial Group purchased a new stake in shares of Revolution Medicines in the third quarter valued at approximately $369,000. Burkett Financial Services LLC purchased a new position in Revolution Medicines during the third quarter worth approximately $27,000. QRG Capital Management Inc. boosted its stake in Revolution Medicines by 31.6% during the second quarter. QRG Capital Management Inc. now owns 8,083 shares of the company’s stock worth $1,514,000 after buying an additional 1,943 shares during the last quarter. Andra AP fonden boosted its stake in Revolution Medicines by 69.9% during the second quarter. Andra AP fonden now owns 28,200 shares of the company’s stock worth $5,281,000 after buying an additional 11,600 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in Revolution Medicines in the 2nd quarter valued at $626,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.